Potential and pitfalls of therapy with α-particles

Journal of Nuclear Medicine

Volumn 46, Issue 8, 2005, Pages 1254-1255

  Welch, Michael J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASTATINE 211; BISMUTH; CARBON 11; POLONIUM; RADIOPHARMACEUTICAL AGENT; ASTATINE; RADIOISOTOPE;

ALPHA RADIATION; CANCER RADIOTHERAPY; CYCLOTRON; HALF LIFE TIME; HUMAN; ISOTOPE LABELING; LINEAR ENERGY TRANSFER; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOISOTOPE DECAY; REVIEW; TUMOR CELL DESTRUCTION; CLINICAL TRIAL; METHODOLOGY; NEOPLASM; NOTE; RADIOIMMUNOTHERAPY;

ALPHA PARTICLES; ASTATINE; CLINICAL TRIALS; HUMANS; NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOPHARMACEUTICALS;

EID: 25444436436     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med. 2005;46(suppl):199S-204S.
2. 131I-labeled monoclonal antibodies? Some dosimetric considerations. Recent Results Cancer Res. 1996;141:67-75.
3. Goldenberg DM. Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother. 2003;52:281-296.
4. Akabani G, Hawkins WG, Eckblade MB, Leichner PK. Patient-specific dosimetry using quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution. J Nucl Med. 1997;33:308-314.
5. Zalutsky, M. Radionuclide therapy. In: Radiochemistry and Radiopharmaceutical Chemistry in Life Sciences. Dordrecht, The Netherlands: Kluwer Academic; 2003. Roesch F, ed. Handbook of Nuclear Chemistry, vol 4:315-348.
6. 225Ac for vascular targeted radioimmunotherapy of lung tumors. Cancer Biother Radiopharm. 2000;15:235-244.
7. 2. Radiochim Acta. 1993;60:1-10.
8. 212Bi. Radiochim Acta. 2003;91:109-114.
9. Turkington TG, Zalutsky MR, Jaszczak RJ, et al. Measuring astatine-211 distributions with SPECT. Phys Med Biol. 1993;33:1121-1130.
10. 211At in small volumes for evaluation of targeted radiotherapy in animal models. Nucl Med Biol. 1995;22:45-54.
11. Zalutsky MR, Vaidyanathan G. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha particle therapy. Curr Pharm Des. 2000;6:1433-1455.
12. 2. Nucl Med Biol. 1993;20:917-927.
13. Wilbur DS, Chyan MK, Hamlin DK, et al. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nidocarboranyl compounds. Bioconjug Chem. 2004;15:203-223.
14. 131I- methylene blue: preclinical and clinical experience. Hybridoma. 1999;18:77-82.
15. 211At] astato-2′-deoxyuridine in human cancer cells. Int J Radiat Biol. 1997;72:79-90.
16. Larsen RH, Akabani G, Welsh P, Zalutsky MR. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro. Radiat Res. 1998;149:155-162.
17. Walicka MA, Vaidyanathan G, Zalutsky MR, Adelstein SJ, Kassis AI. Survival and DNA damage in Chinese hamster V79 cells exposed to alpha particles emitted by DNA-incorported astatine-211. Radiat Res. 1998;150:263-268.
18. Zalutsky M, Welsh P, Akabani G, Zhao X-G. Alpha-particle emitting astatine-211 labeled herceptin is highly cytotoxic for HER-2-expressing breast cancer cells in vitro [abstract]. Proc Am Assoc Cancer Res. 2002;43:431.
19. 211At: analyses of tumour retention, microdistribution and growth delay. Br J Cancer. 1998;77:1115-1122.
20. 2 fragment. Cancer Res. 1990;50:3514-3520.
21. 131I-labeled monoclonal antibody MOv18 in nude mice with intraperitoneal growth of human ovarian cancer. Anticancer Res. 2001;21:409-412.
22. Zalutsky M, Reardon D, Akabani G, et al. Astatine-211 labeled human/mouse chimeric anti-tenascin monoclonal antibody via surgically created resection cavities for patients with recurrent glioma: phase I study [abstract]. Neuro-Oncology. 2002;4(suppl):S103.
23. Zalutsky MR. Targeted radiotherapy of brain tumours. Br J Cancer. 2004;90:1469-1473.
24. 211At-astatobenzoate synthesis. J Nucl Med. 2005;46:1393-1400.
25. Bayly RJ, Evans EA. Stability and storage of compounds labeled with radioisotopes. J Labelled Compd. 1966;2:1-34.
26. 11C-labeled PET radiopharmaceuticals. Appl Radiat Isot. 2004;61:1279-1237.
27. 11C]methionine solutions. J Radioanal Nucl Chem. 2003;256:199-203.
28. 11C]Ro 15-4513. Nucl Med Biol. 2004;30:339-395.
29. 11C]iomazenil solution. Radiochim Acta. 2004;92:119-123.
30. 211At α-particles. J Nucl Med. 2005;46:700-706.